Dapagliflozin

Dapagliflozin, sold under the brand name Farxiga among others, is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes.[2] It is also used to treat adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.[3]

Dapagliflozin
Haworth projection (bottom)
Clinical data
Pronunciation/ˌdæpəɡlɪˈfloʊzɪn/ DAP-ə-glif-LOH-zin
Trade namesForxiga, Farxiga, others
Other namesBMS-512148; (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D [1]
  • US: N (Not classified yet) [1]
    Routes of
    administration    		By mouth (tablets)
    Drug classSodium-glucose co-transporter 2 (SGLT2) inhibitor
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability78% (after 10 mg dose)
    Protein binding~91%
    MetabolismUGT1A9 (major), CYP (minor)
    MetabolitesDapagliflozin 3-O-glucuronide (inactive)
    Elimination half-life~12.9 hours
    ExcretionUrine (75%), feces (21%)[2]
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.167.331
    Chemical and physical data
    FormulaC21H25ClO6
    Molar mass408.873 g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    The most common side effect in people with type 2 diabetes is hypoglycaemia, especially when used in combination with a sulphonylurea or insulin.[4] The most common side effect in people with type 1 diabetes is genital infection, especially in women and a common side effect is diabetic ketoacidosis.[4] It is of the gliflozin (SGLT2 inhibitor) class.[2]

    It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. In 2017, it was the 259th most commonly prescribed medication in the United States, with more than one million prescriptions.[5][6]

    Medical uses

    Dapagliflozin is used along with diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of hospitalization for heart failure among adults with type 2 diabetes and known cardiovascular disease or other risk factors.[7][3] It appears less useful than empagliflozin.[8]

    In the US, it is also indicated for the treatment of adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.[3]

    In the European Union it is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

    • as monotherapy when metformin is considered inappropriate due to intolerance.[4]
    • in addition to other medicinal products for the treatment of type 2 diabetes.[4]

    and for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.[4]

    One study found that it had no benefit on heart disease risk or overall risk of death in people with diabetes.[9] Another study found that in heart failure with a reduced ejection fraction, dapagliflozin reduced the risk of worsening of heart failure or progression to death from cardiovascular causes, irrespective of diabetic status.[10]

    Adverse effects

    Since dapagliflozin leads to heavy glycosuria (sometimes up to about 70 grams per day) it can lead to rapid weight loss and tiredness. The glucose acts as an osmotic diuretic (this effect is the cause of polyuria in diabetes) which can lead to dehydration. The increased amount of glucose in the urine can also worsen the infections already associated with diabetes, particularly urinary tract infections and thrush (candidiasis). Rarely, use of a SGLT2 drug, including dapagliflozin, is associated with necrotizing fasciitis of the perineum, also called Fournier gangrene.[11]

    Dapagliflozin is also associated with hypotensive reactions. There are concerns it may increase the risk of diabetic ketoacidosis.[12]

    Dapagliflozin can cause dehydration, serious urinary tract infections and genital yeast infections.[3] Elderly people, people with kidney problems, those with low blood pressure, and people on diuretics should be assessed for their volume status and kidney function.[3] People with signs and symptoms of metabolic acidosis or ketoacidosis (acid buildup in the blood) should also be assessed.[3] Dapagliflozin can cause serious cases of necrotizing fasciitis of the perineum (Fournier's Gangrene) in people with diabetes and low blood sugar when combined with insulin.[3]

    To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.[13]

    Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.[13]

    Mechanism of action

    Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.[14] In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin.[15]

    Regarding its protective effects in heart failure, this is attributed primarily to haemodynamic effects, where SGLT2 inhibitors potently reduce intravascular volume through osmotic diuresis and natriuresis. This consequently may lead to a reduction in preload and afterload, thereby alleviating cardiac workload and improving left ventricular function.[16]

    Selectivity

    The IC50 for SGLT2 is less than one thousandth of the IC50 for SGLT1 (1.1 versus 1390 nmol/L), so that the drug does not interfere with intestinal glucose absorption.[17]

    Names

    Dapagliflozin is the International nonproprietary name (INN),[18] and the United States Adopted Name (USAN).[19]

    There is a fixed-dose combination product dapagliflozin/metformin extended-release, called Xigduo XR.[20][21][22]

    In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was approved for medical use in the European Union and is sold under the brand name Qtern.[23] The combination drug was approved for medical use in the United States in February 2017, where it is sold under the brand name Qtern.[24][25]

    In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in adults with type 2 diabetes when used in combination with diet and exercise. The FDA granted the approval of Qternmet XR to AstraZeneca.[26] The combination drug was approved for use in the European Union in November 2019, and is sold under the brand name Qtrilmet.[27]

    History

    In 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the drug.[4]

    Dapagliflozin was found effective in several studies in participants with type 2 and type 1 diabetes.[4] The main measure of effectiveness was the level of glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.[4]

    In two studies involving 840 participants with type 2 diabetes, dapagliflozin when used alone decreased HbA1c levels by 0.66 percentage points more than placebo (a dummy treatment) after 24 weeks.[4] In four other studies involving 2,370 participants, adding dapagliflozin to other diabetes medicines decreased HbA1c levels by 0.54-0.68 percentage points more than adding placebo after 24 weeks.[4]

    In a study involving 814 participants with type 2 diabetes, dapagliflozin used in combination with metformin was at least as effective as a sulphonylurea (another type of diabetes medicines) used with metformin.[4] Both combinations reduced HbA1c levels by 0.52 percentage points after 52 weeks.[4]

    A long-term study, involving over 17,000 participants with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease.[4] The study indicated that dapagliflozin's effects were in line with those of other diabetes medicines that also work by blocking SGLT2.[4]

    In two studies involving 1,648 participants with type 1 diabetes whose blood sugar was not controlled well enough on insulin alone, adding dapagliflozin 5 mg decreased HbA1c levels after 24 hours by 0.37% and by 0.42% more than adding placebo.[4]

    Dapagliflozin was approved for medical use in the European Union in November 2012.[4] It is marketed in a number of European countries.[28]

    Dapagliflozin was approved for medical use in the United States in January 2014.[29]

    In 2020, the U.S. Food and Drug Administration (FDA) expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.[3] It is the first in this particular drug class, sodium-glucose co-transporter 2 (SGLT2) inhibitors, to be approved to treat adults with New York Heart Association's functional class II-IV heart failure with reduced ejection fraction.[3]

    Dapagliflozin was shown in a clinical trial to improve survival and reduce the need for hospitalization in adults with heart failure with reduced ejection fraction.[3] The safety and effectiveness of dapagliflozin were evaluated in a randomized, double-blind, placebo-controlled study of 4,744 participants.[3] The average age of participants was 66 years and more participants were male (77%) than female.[3] To determine the drug's effectiveness, investigators examined the occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.[3] Participants were randomly assigned to receive a once-daily dose of either 10 milligrams of dapagliflozin or a placebo (inactive treatment).[3] After about 18 months, people who received dapagliflozin had fewer cardiovascular deaths, hospitalizations for heart failure, and urgent heart failure visits than those receiving the placebo.[3]

    In July 2020, the FDA granted AstraZeneca a Fast Track Designation in the US for the development of dapagliflozin to reduce the risk of hospitalisation for heart failure or cardiovascular death in adults following a heart attack.[30]

    gollark: This is why C needs proper genericoforms.
    gollark: Although in the floating point pointer scheme you can just use NaN.
    gollark: It's a pointroid, so just useify a null pointer to signify None?
    gollark: What's a brachyuraform?
    gollark: Why not port PotatOS to x86 instead?

    References
    1. "Dapagliflozin (Farxiga) Use During Pregnancy". Drugs.com. 30 August 2018. Retrieved 5 May 2020.
    2. "Farxiga- dapagliflozin tablet, film coated". DailyMed. 3 February 2020. Retrieved 5 May 2020.
    3. "FDA approves new treatment for a type of heart failure". U.S. Food and Drug Administration (FDA) (Press release). 5 May 2020. Retrieved 5 May 2020. This article incorporates text from this source, which is in the public domain.
    4. "Forxiga EPAR". European Medicines Agency (EMA). Retrieved 17 February 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    5. "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
    6. "Dapagliflozin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
    7. "FDA Approves Farxiga to Treat Type 2 Diabetes" (Press release). U.S. Food and Drug Administration (FDA). 8 January 2014. Archived from the original on 9 January 2014. Retrieved 15 November 2016. This article incorporates text from this source, which is in the public domain.
    8. Zelniker TA, Wiviott SD, Raz I, et al. (January 2019). "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials". Lancet. 393 (10166): 31–9. doi:10.1016/S0140-6736(18)32590-X. PMID 30424892. However, in patients with atherosclerotic cardiovascular disease, the effect of empagliflozin on cardiovascular death was more pro-nounced than that of canagliflozin or dapagliflozin
    9. "Type 2 diabetes. Cardiovascular assessment of dapagliflozin: no advance". Prescrire International. 29 (211): 23. January 2020. Retrieved 2 February 2020.
    10. McMurray JJ, Solomon SD, Inzucchi SE, et al. (November 2019). "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction". New England Journal of Medicine. 381 (21): 1995–2008. doi:10.1056/NEJMoa1911303. PMID 31535829.
    11. "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 9 February 2019. This article incorporates text from this source, which is in the public domain.
    12. "SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood". U.S. Food and Drug Administration (FDA). 15 May 2015. Archived from the original on 27 October 2016. Retrieved 15 November 2016.
    13. "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Retrieved 6 June 2020. This article incorporates text from this source, which is in the public domain.
    14. "Life Sciences - Clarivate". Clarivate. Archived from the original on 5 November 2007.
    15. "UEndocrine: Internet Endocrinology Community". uendocrine.com. Archived from the original on 5 February 2013.
    16. Lan NS, Fegan PG, Yeap BB, Dwivedi G (October 2019). "The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions". ESC Heart Fail. 6 (5): 927–935. doi:10.1002/ehf2.12505. PMC 6816235. PMID 31400090.
    17. Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
    18. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59" (PDF). World Health Organization. 2008. p. 50. Retrieved 15 November 2016.
    19. "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). American Medical Association. Archived from the original (PDF) on 7 February 2012. Retrieved 15 November 2016.
    20. "US FDA Approves Once-Daily Xigduo XR Tablets for Adults with Type 2 Diabetes". AstraZeneca. 30 October 2014.
    21. "Xigduo XR (dapagliflozin and metformin HCl) Extended-Release Tablets". U.S. Food and Drug Administration (FDA). 7 April 2015. Retrieved 5 May 2020.
    22. "Xigduo XR- dapagliflozin and metformin hydrochloride tablet, film coated, extended release". DailyMed. 3 February 2020. Retrieved 5 May 2020.
    23. "Qtern EPAR". European Medicines Agency (EMA). Retrieved 7 May 2020.
    24. "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 8 May 2020.
    25. "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 17 February 2020.
    26. "Drug Approval Package: Qternmet XR". U.S. Food and Drug Administration (FDA). 27 January 2020. Retrieved 17 February 2020.
    27. "Qtrilmet EPAR". European Medicines Agency (EMA). Retrieved 30 March 2020.
    28. "Forxiga". Drugs.com. 4 May 2020. Retrieved 5 May 2020.
    29. "Drug Approval Package: Farxiga (dapagliflozin) Tablets NDA #202293". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 5 May 2020.
    30. "FARXIGA Granted Fast Track Designation in the US for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design". www.businesswire.com. 16 July 2020. Retrieved 20 July 2020.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.